IBRX

$8.47-0.35 (-3.97%)

Market ClosedAs of Mar 20, 8:00 PM UTC

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$8.47
Potential Upside
5%
Whystock Fair Value$8.89
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product cand...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
73.35%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.08

Recent News

Insider Monkey
Mar 21, 2026

Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era”

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. When a caller inquired about the stock during the lightning round, Cramer said: ImmunityBio had a big cross of a huge amount of stock, but at the end, I don’t know where […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 21, 2026

BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best Robinhood stocks on this list. TheFly reported on March 11 that BTIG gave IBRX a Buy rating and assigned a $13 price target. The firm pointed to the stock’s strong performance in 2026, supported by rapid year-over-year growth in U.S. ANKTIVA sales, conditional marketing authorization in the European Union, and NSCLC approval […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 18, 2026

ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most buzzing stocks to buy with the highest upside potential. On March 9, ImmunityBio announced the resubmission of its sBLA to the FDA for ANKTIVA in combination with Bacillus Calmette-Guérin/BCG. This filing specifically targets patients with BCG-unresponsive non-muscle invasive bladder cancer/NMIBC who present with papillary disease. The resubmission […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 18, 2026

ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference

ImmunityBio (NASDAQ:IBRX) CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress with its lead product ANKTIVA and to highlight multiple upcoming regulatory and clinical milestones across bladder cancer, lung cancer, and earlier-s

BEARISH
Negative press. News cycle fixated on risk factors or misses.
The Wall Street Journal
Mar 18, 2026

The Stubborn Billionaire Behind the L.A. Times’s Revamp

Patrick Soon-Shiong is pursuing a public offering for the media company, while juggling healthcare and tech pursuits.

BEARISH
Negative press. News cycle fixated on risk factors or misses.